So Braidwell just trimmed their Xenon position pretty hard - dumped like 1.78M shares worth $75M back in Q4. Stock was sitting around $42 at the time. Interesting timing since we're now past that March Phase 3 data drop everyone was waiting for on azetukalner. That was supposed to be the big catalyst for Xenon, you know? After the sale, Xenon went from being a top holding down to like 2.6% of their portfolio. Makes sense though - biotech is binary, and you don't want too much riding on one data readout. The fund still holds 1.8M shares worth about $82M, so they didn't completely bail. Xenon's been pretty flat honestly, up only 6% over the past year while other biotech names have gone crazy. They've got five Phase 3 studies running across epilepsy and neuropsych, so there's more shots on goal coming. But yeah, when a big fund starts cutting positions ahead of make-or-break data, you gotta wonder what they're thinking. Either way, the real story for Xenon investors is whether those March results actually moved the needle or if we're looking at another disappointment.